Rapid Medical

Executive Summary

Rapid Medical is an Israeli med‑tech company specializing in responsive, remotely adjustable interventional devices for neurovascular therapy, primarily targeting ischemic and hemorrhagic stroke. Founded in 2008 and headquartered in Yokneam, the company has developed proprietary manufacturing techniques that enable real‑time, patient‑specific control of its tools, such as the TIGERTRIEVER 13 for thrombectomy and the Comaneci embolization system. With a growing clinical evidence base and a commercial footprint spanning over 30 countries, Rapid Medical has established itself as an innovative player in the neurovascular space, addressing critical unmet needs in stroke treatment through differentiated technology. The company is privately held and operates at a commercial stage, focusing on expanding market access and deepening clinical validation. Its devices offer unique advantages in terms of adaptability and precision, positioning it well for continued adoption in interventional neuroradiology. Looking ahead, Rapid Medical is poised to benefit from several near‑term catalysts, including potential regulatory clearances for next‑generation devices, positive data from ongoing or completed clinical studies, and expansion into new geographic markets. The company's ability to demonstrate superior outcomes and cost‑effectiveness will be key to gaining further traction. While specific financial details and recent trial timelines are not publicly available, the company's existing commercial presence and innovative product portfolio suggest a solid foundation for growth. The stroke device market is highly competitive, but Rapid Medical's focus on adjustable, responsive technology differentiates it from traditional fixed‑profile devices, offering potential advantages in complex anatomies.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Next-Generation Embolization Device75% success
• Q4 2026Positive 12-Month Clinical Data from TIGERTRIEVER 13 Study80% success
• Q2 2026Expansion into Asia-Pacific Markets via Distribution Partnerships70% success